Neuroendocrine gastrointestinal tumors - A condensed overview of diagnosis and treatment

Annals of Oncology

Volumn 10, Issue SUPPL. 2, 1999, Pages

  Oberg K ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chemotherapy; Chromogranin A; Octreotide; Receptor scintigraphy; Somatostatin; Surgery; interferon

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALPHA INTERFERON; ANGIOPEPTIN; CHROMOGRANIN A; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; NEUROPEPTIDE K; OCTREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; STREPTOZOCIN; TUMOR MARKER; VAPREOTIDE; YTTRIUM;

ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONFERENCE PAPER; FOLLOW UP; GASTROINTESTINAL TUMOR; HISTOPATHOLOGY; HUMAN; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; SCINTISCANNING; TUMOR DIAGNOSIS;

EID: 0033063306     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_2.S3     Document Type: Conference Paper

References (30)

1. Norheim I, Öberg K, Theodorsson-Norheim E et al. Malignant carcinoid tumours: An analysis of 103 patients with regard to tumour localization hormone production and survival. Ann Surg 1987; 206: 115-25.
2. Eriksson B, Öberg K, Andersson T et al. Neuroendocrine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med 1990; 228: 103-13.
3. Wilander E, Lundqvist ML, Öberg K. Gastrointestinal carcinoid tumors: Progress in histochemistry and cytochemistry. Stuttgart: Gustav Fischer Verlag 1989; 19 (2): 1-88.
4. Goodwin JD. Carcinoid tumors: An analysis of 2837 cases. Cancer 1975; 36: 560-9.
5. Moertel CG, Sauer WG, Dockerty MB et al. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14: 901-12.
6. Stridsberg M, Hellman U, Wilander E et al. Fragments of chromogranin A are present in the urine of patients with carcinoid tumors: Development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol 1993; 139: 329-37.
7. Kwekkeboom DJ, Krenning EP. Somatostatin receptor scintigraphy in patients with carcinoid tumours. World J Surg 1996; 20: 157-61.
8. Janson ET, Westlin JE, Eriksson B et al. 111-In-DTPA-D-Phe octreotide scintigraphy in patients with carcinoid tumours: The predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994; 131: 577-81.
9. Loftur JP, van Heerden JA. Surgical management of gastrointestinal carcinoid tumours. Adv Surg 1995; 28: 317-36.
10. Lang H, Oldhafer KJ, Weimann A et al. Liver transplantation for metastatic neuroendocrine tumours. Ann Surg 1997; 225: 347-54.
11. Marlink RG, Lokich JJ, Robins JR et al. Hepatic arterial embolization for metastatic hormone-secreting tumours. Cancer 1990; 65: 2227-31.
12. Hajarizadeh H, Ivancev K, Mueller C et al. Effective palliative treatment of metastatic carcinoid tumours with intra-arterial chemotherapy/chemoembolisation combined with octreotide acetate. Am J Surg 1992; 163: 479-83.
13. Hoefnagel CA, den Hartog Jager FCA et al. The role of 1-131-MIBG in diagnosis and therapy of carcinoids. Eur J Nucl Med 1987; 13: 187-91.
14. Krenning EP, Valkema P, Kooil PPM et al. Peptide receptor radionuclide therapy with (Indium-111-DTPA-Phe)-Octreotide. J Nucl Med 1997; 38: 47P.
15. Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983; 1 (11): 727-40.
16. Moertel CG. An odyssey in the land of small tumors. J Clin Oncol 1987; 5: 1503-22.
17. Öberg K. The use of chemotherapy in the management of neuroendocrine tumours. Endocrinol Metab Clin North Am 1993; 22: 941-52.
18. Moertel CG, Hanley JA, Johnsson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet cell carcinoma. N Engl J Med 1980; 303: 1189-94.
19. Moertel CG, Kvols LK, O'Conell MJ et al. Treatment of neuroendocrine carcinoima with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-32.
20. Reichlin D. Somatostatin. N Engl J Med 1983; 309: 1495-501, 1556-63.
21. Tiensuu Janson E, Stridsberg M, Gobi A et al. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 1998; 58: 2375-8.
22. Imam H, Eriksson B, Janson ET et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 1997; 36 (6): 607-14.
23. Kvols LK, Moertel CG, O'Connell MJ et al. Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analog. N Engl J Med 1986; 315: 663-6.
24. Arnold R, Trautmann ME, Creutzfeldt W et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 430-8.
25. Rusniewski P, Ducreux M, Chayvialle JA et al. Treatment of the carcinoid syndrome with the long acting somatostatin analogue lanreotide: A prospective study in 39 patients. Gut 1996; 39: 279-83.
26. Öberg K, Funa K, Alm G. Effects of leucocyte interferon upon clinical symptoms and hormone levels in patients with mid-gut carcinoid tumours and the carcinoid syndrome. New Engl J Med 1983; 309: 129-33.
27. Öberg K, Norheim I, Lind E et al. Treatment of malignant carcinoid tumors with human leukocyte interferon. Long-term results. Cancer Treat Resp 1986; 70: 1297-304.
28. Öberg K, Eriksson B, Janson ET. Interferons alone in combination with chemotherapy or other biologicals in the treatment of neuro-endocrine gut and pancreatic tumours. Digestion 1994; 3: 64-9.
29. Jacobsen MB, Hansen LE, Kolmannskog F et al. Interferon-α-2b, with or without prior hepatic artery embolization: Clinical response and survival in mid-gut carcinoid patients: The Norwegian Carcinoid Study. Scand J Gastroenterol 1995; 30 (in press).
30. Tiensuu Janson E, Ahlström H, Andersson T et al. Octreotide and interferon-α: A new combination for the treatment of malignant carcinoid tumors. Eur J Cancer 1992; 28A: 1647-50.